Skip to content
Skip to navigation
Skip to footer

Press Releases

View global media contacts

Latest

AstraZeneca to discover and develop novel therapies targeting RNA-modifying proteins in oncology collaboration with Accent Therapeutics
4 June 2020
Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer
1 June 2020
Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease
1 June 2020
Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial
29 May 2020
Imfinzi showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the Phase III CASPIAN trial
29 May 2020
Enhertu demonstrated meaningful clinical activity in patients with HER2-mutant non-small cell lung cancer in interim analysis of Phase II DESTINY-Lung01 trial
29 May 2020
Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer in Phase II DESTINY-CRC01 trial
29 May 2020
Imfinzi plus tremelimumab demonstrated promising clinical activity and tolerability in patients with advanced liver cancer
29 May 2020
Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-IIIA patients with EGFR-mutated lung cancer
28 May 2020
AstraZeneca collaborates with ArcherDX to use personalised cancer assays to detect minimal residual disease in lung cancer trials
26 May 2020

Can't find what you are looking for? Our Press Release archive contains all of our press releases dated before 2018 so you should be able to find just what you are looking for.

Explore archive